Education
About Us
Working with TipRanks
Follow Us
Adverum Biotechnologies (ADVM)
NASDAQ:ADVM
ADVM Stock Chart & Stats
$4.16
-$0.29(-6.05%)
At close: 4:00 PM EST
$4.16
-$0.29(-6.05%)
Day’s Range― - ―
52-Week Range$1.78 - $6.98
Previous CloseN/A
Volume79.70K
Average Volume (3M)794.40K
Market Cap
$91.84M
Enterprise Value$169.28M
Total Cash (Recent Filing)$26.06M
Total Debt (Recent Filing)$88.94M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Apr 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.03
Shares Outstanding22,077,467
10 Day Avg. Volume378,988
30 Day Avg. Volume794,399
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.31
Price to Sales (P/S)92.38
P/FCF Ratio-0.99
Enterprise Value/Market Cap1.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-364.03
Enterprise Value/Ebitda-0.82
Forecast
1Y Price Target
$4.90Price Target Upside17.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition AgreementThe announced definitive agreement for Eli Lilly to acquire Adverum Biotechnologies is believed to usher in a new chapter for the development of gene therapies in the treatment of wet AMD.
Regulatory SupportThe Ixo-vec program has received Fast Track and Regenerative Medicine Advanced Therapy designations from the FDA, along with PRIME designation from the EMA.
Trial ProgressThe company announced the completion of wet AMD patient screening for its pivotal Phase 3 ARTEMIS trial ahead of expectations, indicating strong demand for their novel gene therapy.
Bears Say
Cash Runway IssuesAdverum was rapidly approaching the end of its cash runway, and the deal represents a better alternative than winding down.
Funding UncertaintyThe need for financing and/or partnership to support ongoing pivotal Ixo-vec development across both the current Phase 3 ARTEMIS trial, and the forthcoming Phase 3 AQUARIUS trial is a concern among investors.
Valuation ConcernsThe transaction size is believed to significantly undervalue the company.
Adverum Biotechnologies News
ADVM FAQ
What was Adverum Biotechnologies’s price range in the past 12 months?
Adverum Biotechnologies lowest stock price was $1.78 and its highest was $6.98 in the past 12 months.
What is Adverum Biotechnologies’s market cap?
Adverum Biotechnologies’s market cap is $91.84M.
When is Adverum Biotechnologies’s upcoming earnings report date?
Adverum Biotechnologies’s upcoming earnings report date is Apr 01, 2026 which is in 124 days.
How were Adverum Biotechnologies’s earnings last quarter?
Adverum Biotechnologies released its earnings results on Nov 06, 2025. The company reported -$2.029 earnings per share for the quarter, missing the consensus estimate of -$1.955 by -$0.074.
Is Adverum Biotechnologies overvalued?
According to Wall Street analysts Adverum Biotechnologies’s price is currently Undervalued.
Does Adverum Biotechnologies pay dividends?
Adverum Biotechnologies does not currently pay dividends.
What is Adverum Biotechnologies’s EPS estimate?
Adverum Biotechnologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Adverum Biotechnologies have?
Adverum Biotechnologies has 22,077,467 shares outstanding.
What happened to Adverum Biotechnologies’s price movement after its last earnings report?
Adverum Biotechnologies reported an EPS of -$2.029 in its last earnings report, missing expectations of -$1.955. Following the earnings report the stock price went down -0.233%.
Which hedge fund is a major shareholder of Adverum Biotechnologies?
Currently, no hedge funds are holding shares in ADVM
Adverum Biotechnologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.90 (17.79% Upside)
$4.90 (17.79% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 15.3%
Last 30 Days ▼ 15.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-31.78%
12-Months-Change
Fundamentals
Return on Equity
-417.79%
Trailing 12-Months
Asset Growth
-69.11%
Trailing 12-Months
Company Description
Adverum Biotechnologies
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
ADVM Stock 12 Month Forecast
Average Price Target
$4.90
▲(17.79% Upside)
Technical Analysis
MacroGenics
―
Armata Pharmaceuticals
―
VistaGen Therapeutics
―
Kalaris Therapeutics
―
Nautilus Biotechnolgy
―
Ownership Overview
15.42% Insiders
6.12% Mutual Funds
30.40% Other Institutional Investors
44.03% Public Companies and
Individual Investors